Evidence map›Paper›PMID 32419808›Full record

ArticleEvidence-based complementary and alternative medicine : eCAM2020

Therapeutic Effect of

Yue Zhao, Xu Yu, Yan Lou, Xinyi Sun, Boyu Zhu, Weilong Xu, Lei Zhou, Hao Wu, Qingzi Jin, Heng Wang and 3 more

Open access · hybridAbstract read
In one paragraph

Article in Evidence-based complementary and alternative medicine : eCAM, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.6field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 1 institution in 1 country.

Yue ZhaoDepartment of Endocrinology, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, China.ORCID https://orcid.org/0000-0001-6739-2190
Xu YuDepartment of Endocrinology, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, China.
Yan LouDepartment of Endocrinology, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, China.
Xinyi SunDepartment of Endocrinology, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, China.
Boyu ZhuDepartment of Endocrinology, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, China.
Weilong XuDepartment of Endocrinology, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, China.
Lei ZhouDepartment of Endocrinology, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, China.
Hao WuDepartment of Ophthalmology, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, China.
Qingzi JinDepartment of Ophthalmology, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, China.
Heng WangDepartment of Laboratory, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, China.
Jianjiang ShenDepartment of Laboratory, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, China.
Jiangyi YuDepartment of Endocrinology, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, China.ORCID https://orcid.org/0000-0003-0691-6979
Xiaofei AnDepartment of Endocrinology, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, China.ORCID https://orcid.org/0000-0002-7683-7988
Nanjing University of Chinese Medicine · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo evaluate the efficacy of

methodsIt was a randomized controlled clinical trial. The recruited eighty subjects with type 2 diabetic nonproliferative retinopathy were randomly divided into treatment group and control group. The two groups received basic treatments including control of blood glucose, blood pressure and blood lipid, management of diet, exercise and health education, and monitoring of relevant indicators. Additionally, the treatment group was given oral administration of

resultsThere were no significant differences of DR severity levels, ETDRS vision scores, macular retinal thicknesses such as cube average thickness (CAT), central subfield thickness (CST), and cube volume (CV), and serum VEGF levels between two groups before treatment. Meanwhile, there were no significant differences of demographic characteristics, case terminations, blood glucose, blood lipid, blood pressure, biochemical indicators of hepatorenal function, hypoglycemic drugs, hypotensive drugs, and other basic treatments between two groups during six months treatment. The present study suggested that the remission rate of DR and the ETDRS vision score in the treatment group were significantly higher than those of the control group (remission rate: 25.4% vs 9.3%,

conclusionThe study offered the novel evidence for the therapeutic effect of

Identifiers

PMID32419808
PMCPMC7210540
OpenAlexW3021010829

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.